Home » Stocks » GKOS

Glaukos Corporation (GKOS)

Stock Price: $83.04 USD 0.41 (0.50%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 3.83B
Revenue (ttm) 237.59M
Net Income (ttm) -82.76M
Shares Out 45.71M
EPS (ttm) -1.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $83.04
Previous Close $82.63
Change ($) 0.41
Change (%) 0.50%
Day's Open 82.54
Day's Range 82.50 - 85.34
Day's Volume 371,736
52-Week Range 34.10 - 99.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Glaukos (GKOS) delivered earnings and revenue surprises of 30.00% and 4.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 days ago - Zacks Investment Research

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

2 days ago - Business Wire

Glaukos (NYSE:GKOS) announces its next round of earnings this Wednesday, May 05. Here is Benzinga's look at Glaukos's Q1 earnings report.

3 days ago - Benzinga

Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

1 week ago - Business Wire

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

2 weeks ago - Business Wire

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

3 weeks ago - Business Wire

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Glaukos (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.

1 month ago - Zacks Investment Research

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

2 months ago - Business Wire

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

2 months ago - Business Wire

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

2 months ago - Business Wire

Glaukos' (GKOS) fourth-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.

2 months ago - Zacks Investment Research

Glaukos Corp (NYSE: GKOS) has announced topline data from the U.S. Phase 3 trial evaluating its corneal cross-linking iLink therapy to treat keratoconus. Keratoconus is characterized by cone-shaped corn...

2 months ago - Benzinga

Glaukos (GKOS) delivered earnings and revenue surprises of 93.75% and 0.29%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Glaukos (NYSE:GKOS) were flat after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 66.67% year over year to ($0.02), which beat the estimate...

2 months ago - Benzinga

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

2 months ago - Business Wire

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

2 months ago - Business Wire

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

3 months ago - Business Wire

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

3 months ago - Business Wire

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

3 months ago - Business Wire

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

3 months ago - Business Wire

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

4 months ago - Business Wire

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

5 months ago - Business Wire

Glaukos' (GKOS) third-quarter results reflect a rise in revenues and recovery in the U.S. Glaucoma franchise.

5 months ago - Zacks Investment Research

Glaukos' (GKOS) third-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.

5 months ago - Zacks Investment Research

Glaukos Corporation (GKOS) CEO Tom Burns on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Glaukos (GKOS) delivered earnings and revenue surprises of 80.43% and 19.63%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

6 months ago - Business Wire

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

6 months ago - Business Wire

San Diego, California--(Newsfile Corp. - September 29, 2020) - The Shareholders Foundation, Inc. announces that a lawsuit was filed for investors who formerly held Avedro, Inc. (AVDR) shares.Investors,...

7 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--Labaton Sucharow LLP, a leading investor rights law firm, announces it is investigating potential securities claims on behalf of former shareholders of Avedro Inc. (NASDAQ: AV...

7 months ago - Business Wire

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

8 months ago - Zacks Investment Research

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

8 months ago - Business Wire

Glaukos Is Still A Good Long-Term Value Despite A Tough 2020

8 months ago - Seeking Alpha

SAN DIEGO, Aug. 18, 2020 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against Glaukos Corporation (NYSE: GKOS) ("Glaukos" or the "Company") for viola...

8 months ago - PRNewsWire

Glaukos' (GKOS) second-quarter results reflect fall in revenues partially mitigated by contribution from Avedro buyout.

8 months ago - Zacks Investment Research

Glaukos Corporation (GKOS) Tom Burns on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Glaukos (GKOS) delivered earnings and revenue surprises of 21.79% and 55.92%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

9 months ago - Business Wire

Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...

9 months ago - Business Wire

Investor confidence is high on Glaukos (GKOS) stock, thanks to solid prospects.

10 months ago - Zacks Investment Research

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

11 months ago - Zacks Investment Research

Glaukos Corporation (GKOS) Tom Burns on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Glaukos (GKOS) witnessed a contraction in gross margin but year-over-year revenue surge in Q1.

1 year ago - Zacks Investment Research

Glaukos (GKOS) delivered earnings and revenue surprises of -25.71% and -0.10%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

About GKOS

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is des... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
Jun 25, 2015
CEO
Thomas Burns
Employees
653
Stock Exchange
NYSE
Ticker Symbol
GKOS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for GKOS stock is "Buy." The 12-month stock price forecast is 89.44, which is an increase of 7.71% from the latest price.

Price Target
$89.44
(7.71% upside)
Analyst Consensus: Buy